TEVA Teva Pharmaceutical Industries Ltd.: Earnings per share for the last twelve months

Teva Pharma (TEVA) - corporate logo

Teva Pharmaceutical Industries (TEVA) is systematically reducing harmful emissions, leveraging its extensive presence in the US, where the company produces every tenth prescription drug. The current YoY ttm net income per share growth on GURU.Markets shows that the latest figure is -28.90. This trend is supported by strategic licenses with biotech startups for the joint production of complex biosimilars.

TEVA: Teva Pharmaceuticals Net earnings per share (EPS TTM) 02/11/2024 - 11/19/2026

Teva Pharmaceutical Industries Ltd. - analytical breakdowns and key metrics (TEVA)

- company stock capitalization data:
Fundamental valuation:Teva Pharmaceuticals (TEVA)
Finished products of Teva Pharma

Analyzing earnings per share (EPS) dynamics is critical for separating fundamental stability from market noise. This metric measures the annual growth rate of net income (TTM), allowing for an assessment of real capital generation efficiency. By analyzing the EPS YoY TTM shift, an investor can determine the rate of change in the asset's yield. For Teva Pharmaceutical Industries (TEVA), the stability of these values is supported by a global network of plants that ensures operational flexibility.